Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trialJosep M. Llovet, Peiguo Cao, Ruocai Xu et al.|The Lancet Oncology|2023Cited by 436
Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III TrialShukui Qin, Chunyi Hao, Zhendong Chen et al.|Journal of Clinical Oncology|2022Cited by 191
Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study.Shukui Qin, Chunyi Hao, Zhendong Chen et al.|Journal of Clinical Oncology|2022Cited by 111